Drugs / VIX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05947617 | Oct 2023 → Apr 2025 | cognitive disorder, long COVID-19 | Neobiosis, LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947617 ↗ |
| Modality | Other / unclassified | “VIX001 is an amniotic fluid product derived from qualified donors.” NCT05947617 ↗ |
| Route | Intravenous | “It will be administered intravenously at three ascending doses: 1 ml, 3 ml, or 10 ml.” NCT05947617 ↗ |